The DOI matches its Crossref record; 221 of the 221 references it cites were found in a registry or an index.
Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Masliah, E., Rockenstein, E., Mante, M., Crews, L., Spencer, B., Adame, A., Patrick, C., Trejo, M., Ubhi, K., Rohn, T. T., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019338 · Cited by 423
RetractedStaging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
Kalia, L. V., & Lang, A. E. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61393-3 · Cited by 6,184
Poewe, W., Seppi, K., Tanner, C. M., Halliday, G. M., Brundin, P., Volkmann, J., Schrag, A.-E., & Lang, A. E. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.13 · Cited by 5,415
The functional anatomy of basal ganglia disorders
Albin, R. L., Young, A. B., & Penney, J. B. (1989) · Trends in Neurosciences · doi:10.1016/0166-2236(89)90074-x · Cited by 5,353
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227
PHARMACOLOGY AND FUNCTIONS OF METABOTROPIC GLUTAMATE RECEPTORS
Conn, P. J., & Pin, J.-P. (1997) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.37.1.205 · Cited by 3,081
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
Finkel, R. S., Mercuri, E., Darras, B. T., Connolly, A. M., Kuntz, N. L., Kirschner, J., Chiriboga, C. A., Saito, K., Servais, L., Tizzano, E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1702752 · Cited by 2,337
International Parkinson's Disease Genomics Consortium (IPDGC), Nalls, M. A., Parkinson's Study Group (PSG) Parkinson's Research: The Organized GENetics Initiative (PROGENI), 23andMe, GenePD, NeuroGenetics Research Consortium (NGRC), Hussman Institute of Human Genomics (HIHG), Investigator, T. A. J. D., (CHARGE), C. F. H. A. A. R. I. G. E., North American Brain Expression Consortium (NABEC), et al. (2014) · Nature Genetics · doi:10.1038/ng.3043 · Cited by 1,895
Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry
Kravitz, A. V., Freeze, B. S., Parker, P. R. L., Kay, K., Thwin, M. T., Deisseroth, K., & Kreitzer, A. C. (2010) · Nature · doi:10.1038/nature09159 · Cited by 1,885
Parkinson, J. (2002) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/jnp.14.2.223 · Cited by 1,628
The many faces of α-synuclein: from structure and toxicity to therapeutic target
Lashuel, H. A., Overk, C. R., Oueslati, A., & Masliah, E. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3406 · Cited by 1,622
What contributes to quality of life in patients with Parkinson's disease?
Schrag, A. (2000) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.69.3.308 · Cited by 1,380
Functional Repression of cAMP Response Element in 6-Hydroxydopamine-treated Neuronal Cells
Chalovich, E. M., Zhu, J.-H., Caltagarone, J., Bowser, R., & Chu, C. T. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602632200 · Cited by 1,371
Concurrent activation of striatal direct and indirect pathways during action initiation
Cui, G., Jun, S. B., Jin, X., Pham, M. D., Vogel, S. S., Lovinger, D. M., & Costa, R. M. (2013) · Nature · doi:10.1038/nature11846 · Cited by 1,301
Kordower, J. H., Emborg, M. E., Bloch, J., Ma, S. Y., Chu, Y., Leventhal, L., McBride, J., Chen, E.-Y., Palfi, S., Roitberg, B. Z., et al. (2000) · Science · doi:10.1126/science.290.5492.767 · Cited by 1,251
Sian, J., Dexter, D. T., Lees, A. J., Daniel, S., Agid, Y., Javoy‐Agid, F., Jenner, P., & Marsden, C. D. (1994) · Annals of Neurology · doi:10.1002/ana.410360305 · Cited by 1,161
Pharmacological agents acting at subtypes of metabotropic glutamate receptors
Schoepp, D. D., Jane, D. E., & Monn, J. A. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(99)00092-1 · Cited by 1,060
Graybiel, A. M. (2000) · Current Biology · doi:10.1016/s0960-9822(00)00593-5 · Cited by 1,051
Finkel, R. S., Chiriboga, C. A., Vajsar, J., Day, J. W., Montes, J., De Vivo, D. C., Yamashita, M., Rigo, F., Hung, G., Schneider, E., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31408-8 · Cited by 1,019
Lang, A. E., Gill, S., Patel, N. K., Lozano, A., Nutt, J. G., Penn, R., Brooks, D. J., Hotton, G., Moro, E., Heywood, P., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20737 · Cited by 983
Neuropathological assessment of Parkinson’s disease: refining the diagnostic criteria
Dickson, D. W., Braak, H., Duda, J. E., Duyckaerts, C., Gasser, T., Halliday, G. M., Hardy, J., Leverenz, J. B., Del Tredici, K., Wszolek, Z. K., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70238-8 · Cited by 972
Oxidative stress and the pathogenesis of Parkinson's disease
Jenner, P., & Olanow, C. W. (1996) · Neurology · doi:10.1212/wnl.47.6_suppl_3.161s · Cited by 971
Functional recovery in parkinsonian monkeys treated with GDNF
Gash, D. M., Zhang, Z., Ovadia, A., Cass, W. A., Yi, A., Simmerman, L., Russell, D., Martin, D., Lapchak, P. A., Collins, F., et al. (1996) · Nature · doi:10.1038/380252a0 · Cited by 955
Cummings, J., Isaacson, S., Mills, R., Williams, H., Chi-Burris, K., Corbett, A., Dhall, R., & Ballard, C. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62106-6 · Cited by 954
Kaushik, S., & Cuervo, A. M. (2015) · Nature Medicine · doi:10.1038/nm.4001 · Cited by 899
Athauda, D., Maclagan, K., Skene, S. S., Bajwa-Joseph, M., Letchford, D., Chowdhury, K., Hibbert, S., Budnik, N., Zampedri, L., Dickson, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31585-4 · Cited by 889
Obeso, J. A., Stamelou, M., Goetz, C. G., Poewe, W., Lang, A. E., Weintraub, D., Burn, D., Halliday, G. M., Bezard, E., Przedborski, S., et al. (2017) · Movement Disorders · doi:10.1002/mds.27115 · Cited by 859
Mitochondrial dysfunction in Parkinson's disease
Bose, A., & Beal, M. F. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13731 · Cited by 841
Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD
Nutt, J. G., Burchiel, K. J., Comella, C. L., Jankovic, J., Lang, A. E., Laws, E. R., Lozano, A. M., Penn, R. D., Simpson, R. K., Stacy, M., et al. (2003) · Neurology · doi:10.1212/wnl.60.1.69 · Cited by 824
Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia
Picconi, B., Centonze, D., Håkansson, K., Bernardi, G., Greengard, P., Fisone, G., Cenci, M. A., & Calabresi, P. (2003) · Nature Neuroscience · doi:10.1038/nn1040 · Cited by 821
Prion-like transmission of protein aggregates in neurodegenerative diseases
Brundin, P., Melki, R., & Kopito, R. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2873 · Cited by 778
Mitochondrial dysfunction in Parkinson's disease
Winklhofer, K. F., & Haass, C. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.08.013 · Cited by 688
Amantadine in the Treatment of Parkinson's Disease
Schwab, R. S. (1969) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1969.03160070046011 · Cited by 664
Metabotropic glutamate receptors: From the workbench to the bedside
Nicoletti, F., Bockaert, J., Collingridge, G. L., Conn, P. J., Ferraguti, F., Schoepp, D. D., Wroblewski, J. T., & Pin, J. P. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.10.022 · Cited by 653
Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats
Carta, M., Carlsson, T., Kirik, D., & Bjorklund, A. (2007) · Brain · doi:10.1093/brain/awm082 · Cited by 636
Genetic or Pharmacological Iron Chelation Prevents MPTP-Induced Neurotoxicity In Vivo
Kaur, D., Yantiri, F., Rajagopalan, S., Kumar, J., Mo, J. Q., Boonplueang, R., Viswanath, V., Jacobs, R., Yang, L., Beal, M. F., et al. (2003) · Neuron · doi:10.1016/s0896-6273(03)00126-0 · Cited by 620
Targeting Chelatable Iron as a Therapeutic Modality in Parkinson's Disease
Devos, D., Moreau, C., Devedjian, J. C., Kluza, J., Petrault, M., Laloux, C., Jonneaux, A., Ryckewaert, G., Garçon, G., Rouaix, N., et al. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5593 · Cited by 619
Clinical criteria for subtyping Parkinson’s disease: biomarkers and longitudinal progression
Fereshtehnejad, S.-M., Zeighami, Y., Dagher, A., & Postuma, R. B. (2017) · Brain · doi:10.1093/brain/awx118 · Cited by 613
Understanding Dopaminergic Cell Death Pathways in Parkinson Disease
Michel, P. P., Hirsch, E. C., & Hunot, S. (2016) · Neuron · doi:10.1016/j.neuron.2016.03.038 · Cited by 600
Functional changes of the basal ganglia circuitry in Parkinson's disease
Blandini, F., Nappi, G., Tassorelli, C., & Martignoni, E. (2000) · Progress in Neurobiology · doi:10.1016/s0301-0082(99)00067-2 · Cited by 582
Iron neurochemistry in Alzheimer's disease and Parkinson's disease: targets for therapeutics
Belaidi, A. A., & Bush, A. I. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13425 · Cited by 578
The Synaptic Function of α-Synuclein
Burré, J. (2015) · Journal of Parkinson's Disease · doi:10.3233/jpd-150642 · Cited by 573
LRRK2 activation in idiopathic Parkinson’s disease
Di Maio, R., Hoffman, E. K., Rocha, E. M., Keeney, M. T., Sanders, L. H., De Miranda, B. R., Zharikov, A., Van Laar, A., Stepan, A. F., Lanz, T. A., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar5429 · Cited by 564
Parkinson’s Disease: From Pathogenesis to Pharmacogenomics
Cacabelos, R. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18030551 · Cited by 555
Park, J.-S., Davis, R. L., & Sue, C. M. (2018) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-018-0829-3 · Cited by 516
The Aggregation and Fibrillation of α-Synuclein
Fink, A. L. (2006) · Accounts of Chemical Research · doi:10.1021/ar050073t · Cited by 501
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease
Bastide, M. F., Meissner, W. G., Picconi, B., Fasano, S., Fernagut, P.-O., Feyder, M., Francardo, V., Alcacer, C., Ding, Y., Brambilla, R., et al. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.07.002 · Cited by 475
Mitochondrial dysfunction and oxidative stress in Parkinson's disease and monogenic parkinsonism
Hauser, D. N., & Hastings, T. G. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.10.011 · Cited by 474
Axonal Transport Defects in Neurodegenerative Diseases
Morfini, G. A., Burns, M., Binder, L. I., Kanaan, N. M., LaPointe, N., Bosco, D. A., Brown, R. H., Brown, H., Tiwari, A., Hayward, L., et al. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3463-09.2009 · Cited by 464
Wagner, J., Ryazanov, S., Leonov, A., Levin, J., Shi, S., Schmidt, F., Prix, C., Pan-Montojo, F., Bertsch, U., Mitteregger-Kretzschmar, G., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1114-9 · Cited by 457
Palfi, S., Gurruchaga, J. M., Ralph, G. S., Lepetit, H., Lavisse, S., Buttery, P. C., Watts, C., Miskin, J., Kelleher, M., Deeley, S., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61939-x · Cited by 450
Self-citationLiving on the edge with too many mouths to feed: Why dopamine neurons die
Bolam, J. P., & Pissadaki, E. K. (2012) · Movement Disorders · doi:10.1002/mds.25135 · Cited by 436
Targeting adenosine A2A receptors in Parkinson's disease
Schwarzschild, M. A., Agnati, L., Fuxe, K., Chen, J.-F., & Morelli, M. (2006) · Trends in Neurosciences · doi:10.1016/j.tins.2006.09.004 · Cited by 433
Schrag, A., Siddiqui, U. F., Anastasiou, Z., Weintraub, D., & Schott, J. M. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30328-3 · Cited by 425
Langston, J. W. (2017) · Journal of Parkinson’s Disease · doi:10.3233/jpd-179006 · Cited by 424
The Parkinson Study Group QE3 Investigators, Beal, M. F., Oakes, D., Shoulson, I., Henchcliffe, C., Galpern, W. R., Haas, R., Juncos, J. L., Nutt, J. G., Voss, T. S., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.131 · Cited by 408
Self-citationChung, C. Y., Koprich, J. B., Siddiqi, H., & Isacson, O. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.5427-08.2009 · Cited by 391
Athauda, D., & Foltynie, T. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.01.013 · Cited by 383
Lang, A. E., & Espay, A. J. (2018) · Movement Disorders · doi:10.1002/mds.27360 · Cited by 370
Distinct subclasses of medium spiny neurons differentially regulate striatal motor behaviors
Bateup, H. S., Santini, E., Shen, W., Birnbaum, S., Valjent, E., Surmeier, D. J., Fisone, G., Nestler, E. J., & Greengard, P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009874107 · Cited by 360
Effect of selective LRRK2 kinase inhibition on nonhuman primate lung
Fuji, R. N., Flagella, M., Baca, M., S. Baptista, M. A., Brodbeck, J., Chan, B. K., Fiske, B. K., Honigberg, L., Jubb, A. M., Katavolos, P., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa3634 · Cited by 352
Pissadaki, E. K., & Bolam, J. P. (2013) · Frontiers in Computational Neuroscience · doi:10.3389/fncom.2013.00013 · Cited by 348
The two-century journey of Parkinson disease research
Przedborski, S. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.25 · Cited by 345
Metabotropic glutamate receptors in the basal ganglia motor circuit
Conn, P. J., Battaglia, G., Marino, M. J., & Nicoletti, F. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1763 · Cited by 330
Insulin resistance and Parkinson’s disease: A new target for disease modification?
Athauda, D., & Foltynie, T. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.10.001 · Cited by 328
Moore, T. J., Glenmullen, J., & Mattison, D. R. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.5262 · Cited by 324
Games, D., Valera, E., Spencer, B., Rockenstein, E., Mante, M., Adame, A., Patrick, C., Ubhi, K., Nuber, S., Sacayon, P., et al. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.5314-13.2014 · Cited by 322
Krystal, J. H., Perry, E. B., Gueorguieva, R., Belger, A., Madonick, S. H., Abi-Dargham, A., Cooper, T. B., MacDougall, L., Abi-Saab, W., & D’Souza, D. C. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.9.985 · Cited by 317
Jankovic, J., Goodman, I., Safirstein, B., Marmon, T. K., Schenk, D. B., Koller, M., Zago, W., Ness, D. K., Griffith, S. G., Grundman, M., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.1487 · Cited by 301
Randomized trial of the adenosine A 2A receptor antagonist istradefylline in advanced PD
Hauser, R. A., Hubble, J. P., Truong, D. D., & the Istradefylline US-001 Study Group (2003) · Neurology · doi:10.1212/01.wnl.0000081227.84197.0b · Cited by 300
Self-citationMotor and Cognitive Advantages Persist 12 Months After Exenatide Exposure in Parkinson’s Disease
Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Kahan, J., Ell, P., Whitton, P., Wyse, R., Isaacs, T., Lees, A., et al. (2014) · Journal of Parkinson's Disease · doi:10.3233/jpd-140364 · Cited by 299
Alpha-synuclein and Protein Degradation Systems: a Reciprocal Relationship
Xilouri, M., Brekk, O. R., & Stefanis, L. (2013) · Molecular Neurobiology · doi:10.1007/s12035-012-8341-2 · Cited by 299
Long-Term Evaluation of a Phase 1 Study of AADC Gene Therapy for Parkinson's Disease
Mittermeyer, G., Christine, C. W., Rosenbluth, K. H., Baker, S. L., Starr, P., Larson, P., Kaplan, P. L., Forsayeth, J., Aminoff, M. J., & Bankiewicz, K. S. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.220 · Cited by 298
Therapies targeting DNA and RNA in Huntington's disease
Wild, E. J., & Tabrizi, S. J. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30280-6 · Cited by 298
D2R striatopallidal neurons inhibit both locomotor and drug reward processes
Durieux, P. F., Bearzatto, B., Guiducci, S., Buch, T., Waisman, A., Zoli, M., Schiffmann, S. N., & de Kerchove d'Exaerde, A. (2009) · Nature Neuroscience · doi:10.1038/nn.2286 · Cited by 297
The Metabotropic Glutamate Receptors: Structure, Activation Mechanism and Pharmacology
Pin, J.-P., & Acher, F. (2002) · Current Drug Target -CNS & Neurological Disorders · doi:10.2174/1568007023339328 · Cited by 294
Meltzer, H. Y., Mills, R., Revell, S., Williams, H., Johnson, A., Bahr, D., & Friedman, J. H. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.176 · Cited by 292
α-Synuclein–Induced Down-Regulation of Nurr1 Disrupts GDNF Signaling in Nigral Dopamine Neurons
Decressac, M., Kadkhodaei, B., Mattsson, B., Laguna, A., Perlmann, T., & Björklund, A. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004676 · Cited by 290
Warren Olanow, C., Bartus, R. T., Baumann, T. L., Factor, S., Boulis, N., Stacy, M., Turner, D. A., Marks, W., Larson, P., Starr, P. A., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24436 · Cited by 287
Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial
(2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00144-1 · Cited by 286
Ko, H. S., Lee, Y., Shin, J.-H., Karuppagounder, S. S., Gadad, B. S., Koleske, A. J., Pletnikova, O., Troncoso, J. C., Dawson, V. L., & Dawson, T. M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1006083107 · Cited by 283
Levodopa in Parkinson’s Disease: Current Status and Future Developments
Tambasco, N., Romoli, M., & Calabresi, P. (2018) · Current Neuropharmacology · doi:10.2174/1570159x15666170510143821 · Cited by 282
Therapeutic potential of autophagy-enhancing agents in Parkinson’s disease
Moors, T. E., Hoozemans, J. J. M., Ingrassia, A., Beccari, T., Parnetti, L., Chartier-Harlin, M.-C., & van de Berg, W. D. J. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0154-3 · Cited by 278
The systemic availability of oral glutathione
Witschi, A., Reddy, S., Stofer, B., & Lauterburg, B. H. (1992) · European Journal of Clinical Pharmacology · doi:10.1007/bf02284971 · Cited by 273
Minakaki, G., Menges, S., Kittel, A., Emmanouilidou, E., Schaeffner, I., Barkovits, K., Bergmann, A., Rockenstein, E., Adame, A., Marxreiter, F., et al. (2018) · Autophagy · doi:10.1080/15548627.2017.1395992 · Cited by 272
The heterogeneity of idiopathic Parkinson's disease
Foltynie, T., Brayne, C., & Barker, R. A. (2002) · Journal of Neurology · doi:10.1007/pl00007856 · Cited by 255
Goetz, C. G., Wuu, J., McDermott, M. P., Adler, C. H., Fahn, S., Freed, C. R., Hauser, R. A., Olanow, W. C., Shoulson, I., Tandon, P. K., et al. (2008) · Movement Disorders · doi:10.1002/mds.21894 · Cited by 253
Self-citationEffects of a central cholinesterase inhibitor on reducing falls in Parkinson disease
Chung, K. A., Lobb, B. M., Nutt, J. G., & Horak, F. B. (2010) · Neurology · doi:10.1212/wnl.0b013e3181f6128c · Cited by 252
First‐in‐human assessment of PRX002, an anti–α‐synuclein monoclonal antibody, in healthy volunteers
Schenk, D. B., Koller, M., Ness, D. K., Griffith, S. G., Grundman, M., Zago, W., Soto, J., Atiee, G., Ostrowitzki, S., & Kinney, G. G. (2017) · Movement Disorders · doi:10.1002/mds.26878 · Cited by 252
Sardi, S. P., Clarke, J., Viel, C., Chan, M., Tamsett, T. J., Treleaven, C. M., Bu, J., Sweet, L., Passini, M. A., Dodge, J. C., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1220464110 · Cited by 251
Amantadine Inhibits NMDA Receptors by Accelerating Channel Closure during Channel Block
Blanpied, T. A., Clarke, R. J., & Johnson, J. W. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4262-04.2005 · Cited by 251
Are synucleinopathies prion-like disorders?
Angot, E., Steiner, J. A., Hansen, C., Li, J.-Y., & Brundin, P. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70213-1 · Cited by 251
Dysregulation of glucose metabolism is an early event in sporadic Parkinson's disease
Dunn, L., Allen, G. F., Mamais, A., Ling, H., Li, A., Duberley, K. E., Hargreaves, I. P., Pope, S., Holton, J. L., Lees, A., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.11.001 · Cited by 243
Surmeier, D. J., Guzman, J. N., Sanchez-Padilla, J., & Schumacker, P. T. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.08.045 · Cited by 236
Yang, L., Calingasan, N. Y., Wille, E. J., Cormier, K., Smith, K., Ferrante, R. J., & Flint Beal, M. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06074.x · Cited by 231
The relationship between glucocerebrosidase mutations and Parkinson disease
Migdalska‐Richards, A., & Schapira, A. H. V. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13385 · Cited by 231
Mandler, M., Valera, E., Rockenstein, E., Weninger, H., Patrick, C., Adame, A., Santic, R., Meindl, S., Vigl, B., Smrzka, O., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1256-4 · Cited by 229
Prakash, K. M., Nadkarni, N. V., Lye, W. ‐., Yong, M. ‐., & Tan, E. ‐. (2016) · European Journal of Neurology · doi:10.1111/ene.12950 · Cited by 229
Reversible Conformational Conversion of α-Synuclein into Toxic Assemblies by Glucosylceramide
Zunke, F., Moise, A. C., Belur, N. R., Gelyana, E., Stojkovska, I., Dzaferbegovic, H., Toker, N. J., Jeon, S., Fredriksen, K., & Mazzulli, J. R. (2018) · Neuron · doi:10.1016/j.neuron.2017.12.012 · Cited by 223
Stahl, S. M. (2016) · CNS Spectrums · doi:10.1017/s1092852916000407 · Cited by 221
Imam, S. Z., Zhou, Q., Yamamoto, A., Valente, A. J., Ali, S. F., Bains, M., Roberts, J. L., Kahle, P. J., Clark, R. A., & Li, S. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.1833-10.2011 · Cited by 214
Ambroxol effects in glucocerebrosidase and α‐synuclein transgenic mice
Migdalska‐Richards, A., Daly, L., Bezard, E., & Schapira, A. H. V. (2016) · Annals of Neurology · doi:10.1002/ana.24790 · Cited by 204
Tarrade, A., Fassier, C., Courageot, S., Charvin, D., Vitte, J., Peris, L., Thorel, A., Mouisel, E., Fonknechten, N., Roblot, N., et al. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl431 · Cited by 202
Self-citationProgression marker of Parkinson’s disease: a 4-year multi-site imaging study
Burciu, R. G., Ofori, E., Archer, D. B., Wu, S. S., Pasternak, O., McFarland, N. R., Okun, M. S., & Vaillancourt, D. E. (2017) · Brain · doi:10.1093/brain/awx146 · Cited by 200
Hauser, R. A., Cantillon, M., Pourcher, E., Micheli, F., Mok, V., Onofrj, M., Huyck, S., & Wolski, K. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70012-6 · Cited by 194
Self-citationCellular and Molecular Basis of Neurodegeneration in Parkinson Disease
Zeng, X.-S., Geng, W.-S., Jia, J.-J., Chen, L., & Zhang, P.-P. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00109 · Cited by 193
Moreau, C., Delval, A., Defebvre, L., Dujardin, K., Duhamel, A., Petyt, G., Vuillaume, I., Corvol, J.-C., Brefel-Courbon, C., Ory-Magne, F., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70106-0 · Cited by 192
Self-citationTargeting dysregulation of brain iron homeostasis in Parkinson's disease by iron chelators
Weinreb, O., Mandel, S., Youdim, M. B. H., & Amit, T. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.01.017 · Cited by 190
Functional connectivity in the basal ganglia network differentiates PD patients from controls
Szewczyk-Krolikowski, K., Menke, R. A. L., Rolinski, M., Duff, E., Salimi-Khorshidi, G., Filippini, N., Zamboni, G., Hu, M. T. M., & Mackay, C. E. (2014) · Neurology · doi:10.1212/wnl.0000000000000592 · Cited by 189
Coenzyme Q10 effects in neurodegenerative disease
Henchcliffe, C. (2009) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s5212 · Cited by 188
Dopamine Gene Therapy for Parkinson’s Disease in a Nonhuman Primate Without Associated Dyskinesia
Jarraya, B., Boulet, S., Scott Ralph, G., Jan, C., Bonvento, G., Azzouz, M., Miskin, J. E., Shin, M., Delzescaux, T., Drouot, X., et al. (2009) · Science Translational Medicine · doi:10.1126/scitranslmed.3000130 · Cited by 186
Swanson, C. R., Joers, V., Bondarenko, V., Brunner, K., Simmons, H. A., Ziegler, T. E., Kemnitz, J. W., Johnson, J. A., & Emborg, M. E. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-91 · Cited by 186
Bourdenx, M., Koulakiotis, N. S., Sanoudou, D., Bezard, E., Dehay, B., & Tsarbopoulos, A. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.07.003 · Cited by 185
The concept of alpha-synuclein as a prion-like protein: ten years after
Steiner, J. A., Quansah, E., & Brundin, P. (2018) · Cell and Tissue Research · doi:10.1007/s00441-018-2814-1 · Cited by 183
Agarwal, S., Yadav, A., & Chaturvedi, R. K. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.08.043 · Cited by 180
GBA1 deficiency negatively affects physiological α-synuclein tetramers and related multimers
Kim, S., Yun, S. P., Lee, S., Umanah, G. E., Bandaru, V. V. R., Yin, X., Rhee, P., Karuppagounder, S. S., Kwon, S.-H., Lee, H., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1700465115 · Cited by 178
Pahwa, R., Tanner, C. M., Hauser, R. A., Isaacson, S. H., Nausieda, P. A., Truong, D. D., Agarwal, P., Hull, K. L., Lyons, K. E., Johnson, R., et al. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2017.0943 · Cited by 177
Self-citationAchieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease
West, A. B. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2017.07.019 · Cited by 176
AFQ056 treatment of levodopa‐induced dyskinesias: Results of 2 randomized controlled trials
Berg, D., Godau, J., Trenkwalder, C., Eggert, K., Csoti, I., Storch, A., Huber, H., Morelli‐Canelo, M., Stamelou, M., Ries, V., et al. (2011) · Movement Disorders · doi:10.1002/mds.23616 · Cited by 175
Animal models of Parkinson's disease: Limits and relevance to neuroprotection studies
Bezard, E., Yue, Z., Kirik, D., & Spillantini, M. G. (2013) · Movement Disorders · doi:10.1002/mds.25108 · Cited by 173
The MPTP-lesioned non-human primate models of Parkinson’s disease. Past, present, and future
Fox, S. H., & Brotchie, J. M. (2010) · Progress in brain research · doi:10.1016/s0079-6123(10)84007-5 · Cited by 172
Parkinson’s disease as a system-level disorder
Caligiore, D., Helmich, R. C., Hallett, M., Moustafa, A. A., Timmermann, L., Toni, I., & Baldassarre, G. (2016) · npj Parkinson's Disease · doi:10.1038/npjparkd.2016.25 · Cited by 171
Targeted Therapies for Parkinson's Disease: From Genetics to the Clinic
Sardi, S. P., Cedarbaum, J. M., & Brundin, P. (2018) · Movement Disorders · doi:10.1002/mds.27414 · Cited by 170
Remondelli, P., & Renna, M. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00187 · Cited by 169
Parkinson's Disease Gene Therapy: Success by Design Meets Failure by Efficacy
Bartus, R. T., Weinberg, M. S., & Samulski, R. J. (2014) · Molecular Therapy · doi:10.1038/mt.2013.281 · Cited by 164
Non-dopaminergic Treatments for Motor Control in Parkinson’s Disease
Fox, S. H. (2013) · Drugs · doi:10.1007/s40265-013-0105-4 · Cited by 162
Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson’s disease: a dose-finding study
Svenningsson, P., Rosenblad, C., af Edholm Arvidsson, K., Wictorin, K., Keywood, C., Shankar, B., Lowe, D. A., Björklund, A., & Widner, H. (2015) · Brain · doi:10.1093/brain/awu409 · Cited by 162
Therapeutic effects of coenzyme Q10 (CoQ10) and reduced CoQ10 in the MPTP model of Parkinsonism
Cleren, C., Yang, L., Lorenzo, B., Calingasan, N. Y., Schomer, A., Sireci, A., Wille, E. J., & Beal, M. F. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05097.x · Cited by 160
Alpha-Synuclein: From Early Synaptic Dysfunction to Neurodegeneration
Ghiglieri, V., Calabrese, V., & Calabresi, P. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00295 · Cited by 159
α-Synuclein Suppression by Targeted Small Interfering RNA in the Primate Substantia Nigra
McCormack, A. L., Mak, S. K., Henderson, J. M., Bumcrot, D., Farrer, M. J., & Di Monte, D. A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012122 · Cited by 158
A de novo compound targeting α-synuclein improves deficits in models of Parkinson's disease
Wrasidlo, W., Tsigelny, I. F., Price, D. L., Dutta, G., Rockenstein, E. M., Schwarz, T. C., Ledolter, K., Bonhaus, D. W., Paulino, A., Eleuteri, S., et al. (2016) · Brain · doi:10.1093/brain/aww238 · Cited by 155
Amantadine extended release for levodopa‐induced dyskinesia in Parkinson's disease (EASED Study)
Pahwa, R., Tanner, C. M., Hauser, R. A., Sethi, K. D., Isaacson, S., Truong, D. D., Struck, L. K., Ruby, A. E., McClure, N., Went, G. T., et al. (2015) · Movement Disorders · doi:10.1002/mds.26159 · Cited by 152
Self-citationWithdrawing amantadine in dyskinetic patients with Parkinson disease: The AMANDYSK trial
Ory‐Magne, F., Corvol, J., Azulay, J., Bonnet, A.-M., Brefel‐Courbon, C., Damier, P., Dellapina, E., Destée, A., Durif, F., Galitzky, M., et al. (2013) · Neurology · doi:10.1212/wnl.0000000000000050 · Cited by 149
Self-citationGenetic mouse models of Parkinson’s disease
Magen, I., & Chesselet, M. (2010) · Progress in brain research · doi:10.1016/s0079-6123(10)84004-x · Cited by 147
Jaunarajs, K. L. E., Gupta, V., Alam, S., Park, J. Y., & Bishop, C. (2007) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2007.05.002 · Cited by 144
Tison, F., Keywood, C., Wakefield, M., Durif, F., Corvol, J., Eggert, K. M., Lew, M., Isaacson, S., Bézard, E., Poli, S.-M., et al. (2016) · Movement Disorders · doi:10.1002/mds.26659 · Cited by 144
Self-citationRandomized, double‐blind, pilot evaluation of intravenous glutathione in Parkinson's disease
Hauser, R. A., Lyons, K. E., McClain, T., Carter, S., & Perlmutter, D. (2009) · Movement Disorders · doi:10.1002/mds.22401 · Cited by 143
Self-citationBourdenx, M., Doveró, S., Engeln, M., Bido, S., Bastide, M. F., Dutheil, N., Vollenweider, I., Baud, L., Piron, C., Grouthier, V., et al. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0222-2 · Cited by 141
A Long-Term Study of Istradefylline Safety and Efficacy in Patients With Parkinson Disease
Kondo, T., & Mizuno, Y. (2015) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000073 · Cited by 141
The Role of Co-chaperones in Synaptic Proteostasis and Neurodegenerative Disease
Gorenberg, E. L., & Chandra, S. S. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00248 · Cited by 140
Parkinson’s disease: a review of non-motor symptoms
Rana, A. Q., Ahmed, U. S., Chaudry, Z. M., & Vasan, S. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1038244 · Cited by 139
Glucocerebrosidase Mutations in Parkinson Disease
O’Regan, G. C., deSouza, R., Balestrino, R., & Schapira, A. H. V. (2017) · Journal of Parkinson s Disease · doi:10.3233/jpd-171092 · Cited by 136
Hauser, R. A., Olanow, C. W., Kieburtz, K. D., Pourcher, E., Axelerad, A. D., Lew, M., Kozyolkin, О. А., Neale, A. C., Resburg, C., Meya, U., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70148-6 · Cited by 132
Self-citationRecent advances in treating Parkinson’s disease
Oertel, W. H. (2017) · F1000Research · doi:10.12688/f1000research.10100.1 · Cited by 125
Cerebrospinal fluid biomarkers for Parkinson's disease - a systematic review
Andersen, A. D., Binzer, M., Stenager, E., & Gramsbergen, J. B. (2016) · Acta Neurologica Scandinavica · doi:10.1111/ane.12590 · Cited by 123
Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias
Rascol, O., Fox, S. H., Gasparini, F., Kenney, C., Paolo, T. D., & Gomez‐Mancilla, B. (2014) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2014.05.003 · Cited by 122
Self-citationInhibitory Basal Ganglia Inputs Induce Excitatory Motor Signals in the Thalamus
Kim, J.-J., Kim, Y., Nakajima, R., Shin, A., Jeong, M., Park, A. H., Jeong, Y., Jo, S., Yang, S., Park, H., et al. (2017) · Neuron · doi:10.1016/j.neuron.2017.08.028 · Cited by 121
Mitochondria, lysosomes, and dysfunction: their meaning in neurodegeneration
Audano, M., Schneider, A., & Mitro, N. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14471 · Cited by 119
Glucocerebrosidase mutations and the pathogenesis of Parkinson disease
Beavan, M. S., & Schapira, A. H. V. (2013) · Annals of Medicine · doi:10.3109/07853890.2013.849003 · Cited by 115
Levodopa-induced dyskinesia in Parkinson?s disease
Brotchie, J. M., Lee, J., & Venderová, K. (2004) · Journal of Neural Transmission · doi:10.1007/s00702-004-0251-7 · Cited by 114
Grégoire, L., Morin, N., Ouattara, B., Gasparini, F., Bilbe, G., Johns, D. R., Vranesic, I., Sahasranaman, S., Gomez‐Mancilla, B., & Paolo, T. D. (2011) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2011.01.008 · Cited by 109
Phase IIb Study of Intranasal Glutathione in Parkinson’s Disease
Mischley, L. K., Lau, R. C., Shankland, E. G., Wilbur, T. K., & Padowski, J. M. (2017) · Journal of Parkinson s Disease · doi:10.3233/jpd-161040 · Cited by 106
Marshall, J., Sun, Y., Bangari, D. S., Budman, E., Park, H. J., Nietupski, J. B., Allaire, A., Cromwell, M. A., Wang, B., Grabowski, G. A., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.53 · Cited by 105
Cahill, E., Salery, M., Vanhoutte, P., & Caboche, J. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00172 · Cited by 103
Neuroinflammation - A major cause for striatal dopaminergic degeneration in Parkinson's disease
Kaur, K., Gill, J. S., Bansal, P. K., & Deshmukh, R. R. (2017) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2017.08.3251 · Cited by 103
Ambrosi, G., Ghezzi, C., Zangaglia, R., Levandis, G., Pacchetti, C., & Blandini, F. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.06.008 · Cited by 102
Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia
Vijayakumar, D., & Jankovic, J. (2016) · Drugs · doi:10.1007/s40265-016-0566-3 · Cited by 102
NADPH Oxidase 1 Mediates α-Synucleinopathy in Parkinson's Disease
Cristóvão, A. C., Guhathakurta, S., Bok, E., Je, G., Yoo, S. D., Choi, D., & Kim, Y. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.2246-12.2012 · Cited by 101
Erro, R., Picillo, M., Vitale, C., Amboni, M., Moccia, M., Santangelo, G., Pellecchia, M. T., & Barone, P. (2016) · European Journal of Neurology · doi:10.1111/ene.13106 · Cited by 100
Sieber, B.-A., Landis, S. C., Koroshetz, W. J., Bateman, R. J., Siderowf, A. D., Galpern, W. R., Dunlop, J., Finkbeiner, S. M., Sutherland, M. L., Wang, H., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24261 · Cited by 98
Preladenant as an Adjunctive Therapy With Levodopa in Parkinson Disease
Hauser, R. A., Stocchi, F., Rascol, O., Huyck, S. B., Capece, R., Ho, T. W., Sklar, P. A., Lines, C., Michelson, D., & Hewitt, D. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.2268 · Cited by 97
Self-citationPreladenant, a selective A2A receptor antagonist, is active in primate models of movement disorders
Hodgson, R. A., Bédard, P. J., Varty, G. B., Kazdoba, T. M., Paolo, T. D., Grzelak, M. E., Pond, A. J., Tahar, A. H., Bélanger, N., Grégoire, L., et al. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2010.07.011 · Cited by 95
NESS, D. K., Ren, Z., Gardai, S. J., Sharpnack, D. D., Johnson, V. J., Brennan, R., Brigham, E. F., & Olaharski, A. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066164 · Cited by 93
Mitophagy in Parkinson’s Disease: Pathogenic and Therapeutic Implications
Gao, F., Yang, J. Y., Wang, D., Li, C., Fu, Y., Wang, H., He, W., & Zhang, J. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00527 · Cited by 86
Litim, N., Morissette, M., & Paolo, T. D. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.03.036 · Cited by 82
The mGluR5 negative allosteric modulator dipraglurant reduces dyskinesia in the MPTP macaque model
Bézard, E., Pioli, E. Y., Li, Q., Girard, F., Mutel, V., Keywood, C., Tison, F., Rascol, O., & Poli, S. M. (2014) · Movement Disorders · doi:10.1002/mds.25920 · Cited by 81
Self-citationDuty, S. (2012) · CNS Drugs · doi:10.1007/s40263-012-0016-z · Cited by 77
Buspirone in the treatment of levodopa induced dyskinesias.
Kleedorfer, B., Lees, A. J., & Stern, G. M. (1991) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.54.4.376-a · Cited by 76
Challenges in detecting disease modification in Parkinson's disease clinical trials
Athauda, D. S., & Foltynie, T. (2016) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2016.07.019 · Cited by 75
Hauser, R. A., & Holford, N. H. G. (2002) · Movement Disorders · doi:10.1002/mds.10226 · Cited by 74
Self-citationSafinamide reduces dyskinesias and prolongs l-DOPA antiparkinsonian effect in parkinsonian monkeys
Grégoire, L., Jourdain, V. A., Townsend, M., Roach, A., & Paolo, T. D. (2013) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2013.01.009 · Cited by 74
Central nervous system uptake of intranasal glutathione in Parkinson’s disease
Mischley, L. K., Conley, K. E., Shankland, E. G., Kavanagh, T. J., Rosenfeld, M. E., Duda, J. E., White, C. C., Wilbur, T. K., Torre, P. U. D. L., & Padowski, J. M. (2016) · npj Parkinson s Disease · doi:10.1038/npjparkd.2016.2 · Cited by 71
Hauser, R. A., Heritier, S. R., Rowse, G. J., Hewitt, L. A., & Isaacson, S. (2016) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000168 · Cited by 66
Self-citationKoprich, J. B., Johnston, T. H., Reyes, G., Omana, V. N., & Brotchie, J. M. (2016) · PLoS ONE · doi:10.1371/journal.pone.0167235 · Cited by 64
Hauser, R. A., Koller, W. C., Hubble, J. P., Malapira, T., Busenbark, K. L., & Olanow, C. W. (2000) · Movement Disorders · doi:10.1002/1531-8257(200005)15:3<485::aid-mds1010>3.0.co;2-f · Cited by 62
Self-citationMcGhee, D. J. M., Ritchie, C. W., Zajicek, J., & Counsell, C. E. (2016) · BMC Neurology · doi:10.1186/s12883-016-0606-3 · Cited by 62
Targeting metabotropic glutamate receptors (mGluRs) in Parkinson's disease
Amalric, M. (2014) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2014.11.001 · Cited by 61
An m G lu4‐ P ositive A llosteric M odulator A lleviates P arkinsonism in P rimates
Charvin, D., Paolo, T. D., Bézard, E., Grégoire, L., Takano, A., Duvey, G., Pioli, E. Y., Halldin, C., Medori, R., & Conquet, F. (2018) · Movement Disorders · doi:10.1002/mds.27462 · Cited by 60
Self-citationOxidative Modification and Its Implications for the Neurodegeneration of Parkinson’s Disease
Zhao, J., Yu, S., Zheng, Y., Yang, H., & Zhang, J. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-9743-3 · Cited by 59
Nondopaminergic Treatments for Parkinson’s Disease: Current and Future Prospects
Freitas, M. E., & Fox, S. H. (2016) · Neurodegenerative Disease Management · doi:10.2217/nmt-2016-0005 · Cited by 59
New concepts in the pathogenesis and presentation of Parkinson’s disease
Sauerbier, A., Qamar, M. A., Rajah, T., & Chaudhuri, К. R. (2016) · Clinical Medicine · doi:10.7861/clinmedicine.16-4-365 · Cited by 59
LRRK2 inhibitors and their potential in the treatment of Parkinson’s disease: current perspectives
Atashrazm, F., & Dzamko, N. L. (2016) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s102191 · Cited by 59
Paolone, G., Brugnoli, A., Arcuri, L., Mercatelli, D., & Morari, M. (2015) · Movement Disorders · doi:10.1002/mds.26326 · Cited by 58
Non-oral dopaminergic therapies for Parkinson’s disease: current treatments and the future
Chaudhuri, К. R., Qamar, M. A., Rajah, T., Loehrer, P. A., Sauerbier, A., Odin, P., & Jenner, P. G. (2016) · npj Parkinson s Disease · doi:10.1038/npjparkd.2016.23 · Cited by 57
Alpha-synuclein-based models of Parkinson's disease
Dehay, B., & Fernagut, P. (2016) · Revue Neurologique · doi:10.1016/j.neurol.2016.04.003 · Cited by 56
Ko, W. K. D., Camus, S. M. J., Li, Q., Yang, J., McGuire, S., Pioli, E. Y., & Bézard, E. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.07.012 · Cited by 55
Neuroprotective Effects of Eexenatide in a Rotenone-Induced Rat Model of Parkinson’s Disease
Aksoy, D., Solmaz, V., Çavuşoğlu, T., Meral, A., Ateş, U., & Erbaş, O. (2017) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2017.05.002 · Cited by 55
Cazorla, M., Kang, U. J., & Kellendonk, C. (2015) · Movement Disorders · doi:10.1002/mds.26282 · Cited by 54
Zhang, D., Mallela, A., Sohn, D., Carroll, F. I., Bencherif, M., Letchworth, S. R., & Quik, M. (2013) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.207639 · Cited by 52
Zeiss, C. J., Allore, H. G., & Beck, A. P. (2017) · PLoS ONE · doi:10.1371/journal.pone.0171790 · Cited by 49
Ko, W. K. D., & Bézard, E. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2017.07.020 · Cited by 49
Response of aged parkinsonian monkeys to in vivo gene transfer of GDNF
Emborg, M. E., Moirano, J. M., Raschke, J., Bondarenko, V., Zufferey, R., Peng, S. C., Ebert, A. D., Joers, V. L., Roitberg, B. Z., Holden, J. E., et al. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.07.022 · Cited by 48
Accumulation of the parkin substrate, FAF1, plays a key role in the dopaminergic neurodegeneration
Sul, J.-W., Park, M., Shin, J., Kim, Y., Yoo, S., Kong, Y., Kwon, K., Lee, Y., & Kim, E. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt006 · Cited by 47
Charvin, D., Pomel, V., Ortiz, M., Frauli, M., Scheffler, S., Steinberg, E., Baron, L., Deshons, L., Rudigier, R., Thiarc, D., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00991 · Cited by 46
Self-citationEmerging Candidate Biomarkers for Parkinson’s Disease: a Review
Saracchi, E. (2014) · Aging and Disease · doi:10.14336/ad.2014.050027 · Cited by 45
Is Exenatide a Treatment for Parkinson’s Disease?
Athauda, D. S., Wyse, R. K. H., Brundin, P., & Foltynie, T. (2017) · Journal of Parkinson s Disease · doi:10.3233/jpd-171192 · Cited by 44
Ciesielska, A., Samaranch, L., Sebastián, W. S., Dickson, D. W., Goldman, S. M., Forsayeth, J., & Bankiewicz, K. S. (2017) · PLoS ONE · doi:10.1371/journal.pone.0169965 · Cited by 39
Oscillatory activity in the basal ganglia and deep brain stimulation
Guridi, J., & Alegre, M. (2016) · Movement Disorders · doi:10.1002/mds.26714 · Cited by 38
Response Assessment Criteria and Their Applications in Lymphoma: Part 2
Moghbel, M. C., Mittra, E., Gallamini, A., Niederkohr, R. D., Chen, D. L., Zukotynski, K., Nadel, H. R., & Kostakoğlu, L. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.184242 · Cited by 38
Cited by
Balestrino, R., & Schapira, A. H. V. (2020) · European Journal of Neurology · doi:10.1111/ene.14108 · Cited by 1,508
In vitro Models of Neurodegenerative Diseases
Slanzi, A., Iannoto, G., Rossi, B., Zenaro, E., & Constantin, G. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00328 · Cited by 290
Microglia-targeting nanotherapeutics for neurodegenerative diseases
Zhao, N., Francis, N. L., Calvelli, H. R., & Moghe, P. V. (2020) · APL Bioengineering · doi:10.1063/5.0013178 · Cited by 104
Xue, C., Li, X., Ba, L., Zhang, M., Yang, Y., Gao, Y., Sun, Z., Han, Q., & Zhao, R. C. (2021) · Aging and disease · doi:10.14336/ad.2020.1221 · Cited by 100
Lee, E. J., Choi, Y., Lee, H. J., Hwang, D. W., & Lee, D. S. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01356-2 · Cited by 89
Metadata
- Authors
- Charvin, D., Medori, R., Hauser, R. A., & Rascol, O.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2018-09-28
- Volume
- 17
- Issue
- 11
- Pages
- 804-822
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2894229433
- Cited by
- 287
- References
- 221
- FWCI
- 6.36
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.